Background. Preexposure prophylaxis (PrEP) with antiretroviral drugs may prevent transmission of human immunodeficiency virus (HIV). Our objective was to predict whether PrEP, in the presence of circulating drug resistance, will reduce the risk of infection with HIV.
The World Health Organization has estimated that 2.5 million individuals become newly infected with HIV every year. This highlights that current ways for preventing transmission, such as the use of condoms and behavioral changes, are not sufficient to limit the spread of HIV infection. Therefore, additional strategies for preventing new infections are urgently needed. Preexposure prophylaxis (PrEP) with antiretroviral drugs is a possible intervention strategy that could prevent the transmission of HIV [1] .
The use of PrEP as a prevention strategy is supported by animal studies that showed that administration of systemic antiretroviral drugs can prevent infections due to simian immunodeficiency virus [2] [3] [4] [5] . Information about the effectiveness of PrEP in humans is limited to a single phase II safety study with tenofovir [6] . The study included 936 female sex workers in West Africa. Two women in the tenofovir group experienced seroconversion, compared with 6 women in the placebo group. Statistical significance was not achieved [6] . More-conclusive evaluations of PrEP are expected in the coming years, when the results of several trials become available [7, 8] .
Drug resistance is an important factor that could jeopardize the success of PrEP. Importantly, resistance to antiretroviral drugs that are proposed to be used as PrEP is already circulating [9, 10] . But the potential impact of circulating resistance on the effectiveness of PrEP is unknown. On the one hand, drug resistance will reduce the prophylactic effectiveness of PrEP. Conversely, this detrimental effect could be counterbalanced by the reduced fitness of drug-resistant HIV, which may result in lower levels of viremia, compared with those resulting from drugsusceptible HIV [11, 12] . Because the amount of virus is a major determinant of the risk of transmission [13] , drug-resistant HIV could be transmitted less easily than drug-susceptible HIV.
In the present study, we used risk equations to analyze the potential effect of systemic PrEP on the risk of acquiring HIV infection and to determine the impact of circulating drug resistance on the effectiveness of PrEp. For this purpose, the monthly risk of infection due to HIV before PrEp became available was compared with the monthly risk after PrEP became available. The ranges of the parameters were chosen for young women (17-29 years of age) from publications on the epidemiology of HIV infection in Manicaland in Zimbabwe [14, 15] . A female population was chosen, because PrEP may provide an alternative mechanism of protection for women whose partners are unwilling to use a condom. Finally, young women are at great risk of acquiring HIV infection, because they frequently have older sexual partners, among whom the prevalence of HIV infection may be as much as 50% [14, 15] .
METHODS
In this study, we used established mathematical equations that described the monthly probability of HIV transmission between susceptible and infected individuals [16 -19] . Similar to the approach followed by Smith et al. [18] , we refined the equations to analyze the level of protection provided before PrEP became available (when condoms were the only means of protection) and after PrEP became available (at varying prevalences of drugresistant HIV infection).
Mathematical equation before PrEP. The mathematical equation describing the monthly risk of infection before PrEP was available includes the prevalence of HIV infection (P), the number of sexual acts per month (n), the probability of HIV transmission from male to female (␤), and the effectiveness of condoms (e c ). Use of a condom reduced the transmission probability per act by a factor (1 Ϫ e c ). The probability that a susceptible person would become infected when condoms were the only means of protection was
Mathematical equation after PrEP. The future use of PrEP is unknown. Therefore, we made assumptions regarding how frequently PrEP would be used. We assumed that the proportion of sexual acts in which any protection (condoms or PrEP) against HIV infection was used would remain the same or increase. An increase in the level of protection was anticipated if PrEP would be used by individuals who currently do not use condoms. To meet our assumptions, we calculated the proportion of sexual acts in which a particular kind of protection would be used on the basis of the current level of condom use (p 0 ). We hypothesized that PrEP would be started in a fraction ␣ of current condom users p 0 . In the remaining proportion of sexual acts (1 Ϫ ␣), condom use would continue as the only safety measure against HIV infection (i.e., p 1 ϭ p 0 (1 Ϫ ␣)). Among the ␣p 0 sexual acts in which PrEP is started, a proportion will use PrEP as the only means of protection (p 2 ), and 1 Ϫ will combine PrEP and condom use (p 3 ). In addition, it was assumed that, in a fraction of sexual acts in which currently no condoms are used (i.e., 1 Ϫ p 0 ), PrEP will be used as the only possible safety measure. Therefore, the fraction p 2 of sexual acts in which PrEP will be used as the only protection equals ␣p 0 ϩ (1 Ϫ p 0 ). Similarly, the proportion p 3 of sexual acts in which condoms and PrEP will be used is ␣p 0 (1 Ϫ ). No protection (p 4 ) will be used in the remaining acts (i.e., 1 Ϫ p 1 Ϫ p 2 Ϫ p 3 ). The fractions p 1 through p 4 add up to 1. To include the uncertainty about future PrEP use, we ranged the values of ␣, , and between 0 and 1.
The expected effectiveness of PrEP is e p . We assumed that PrEP will reduce the transmission probability per act by a factor (1 Ϫ e p ). Also, PrEP taken orally does not change the effectiveness of condoms. This results in the following equation for the monthly risk during the period in which PrEP is available:
Mathematical equation after PrEP in the presence of circulating resistance. Drug resistance will reduce the effectiveness of PrEP by a factor . It is unknown to what extent resistance will diminish the potentially beneficial impact of PrEP. We therefore used a wide-range for and varied its value from 0.5 through 0.9. To study the impact of fitness on the transmission, we reduced the probability of acquiring HIV infection per sexual act by a factor f, which ranged from 0 through 0.3. Because drug resistance is not always associated with reduced fitness [12] , we also analyzed the model by setting the value of f at 0. The proportion of wild-type and drug-resistant HIV strains were W and R, respectively. Adding W and R gives the prevalence of HIV infection. The equation for the monthly risk of infection in the presence of circulating drug resistance is
Analysis of the mathematical equations. Characteristics and ranges of the parameters included in the mathematical equations are summarized in table 1. The mathematical equations were analyzed with uncertainty analysis using 10,000 Monte Carlo simulations. For this purpose, Latin hypercube sampling [20] was used to randomly obtain values for the parameters included in the equations. The randomly collected values were filled out in the mathematical equations to obtain a monthly risk for acquiring HIV infection.
The reduction in the monthly risk for HIV infection after PrEP became available was calculated using different scenarios. First, the risk reduction was calculated by comparing the situation before PrEP availability with the situation after PrEP availability in the absence of drug resistance. Two levels of PrEP effectiveness were used (reduction of transmissibility of 40%-60% and 60%-80%). These levels were based on studies in animals [2] [3] [4] [5] . However, the degree by which PrEP reduced the transmission probability in a human population could be different from that for an animal population because of factors such as noncompliance. Therefore, the Monte Carlo simulations were repeated, and the effectiveness of PrEP was varied from 0 (no impact of PrEP) through 1 (no HIV transmission when PrEP is used).
The final scenarios studied the impact of drug resistance. The impact of drug resistance was studied with the assumption that the prevalence of drug-resistant strains among individuals with HIV infection ranges from 0% through 50%. We first calculated the risk reduction by taking into account that drug-resistant strains have a reduced fitness [12] . As a consequence, the viral load decreases, which would reduce the probability of transmission of HIV. In another scenario, risk reductions were calculated for a more pessimistic situation in which drug resistance does not affect the transmission probability.
Sensitivity analysis. A multivariate sensitivity analysis was performed to determine which factors most strongly predicted the probability of infection with HIV with the calculated risk reduction. For this purpose, the association between the limits of the parameters included in the equations and the ranges of the probability of infection and the risk (reduction) were calculated as partial rank correlation coefficients (PRCCs) [20] . The PRCCs range from Ϫ1 through 1. Parameters with a PRCC Ͼ0 and a PRCC Ͻ0 increase and decrease, respectively, the monthly risk (reduction) for HIV infection. The larger the PRCC, the larger the influence of the input parameter on the magnitude of the risk (reduction).
RESULTS

Impact of PrEP on monthly risk of acquiring HIV infection in
the absence of drug resistance. Analysis of our model showed that the introduction of PrEP generally reduced the monthly risk of HIV acquisition. Table 2 summarizes the risk distribution and the percentage decrease in the monthly risk for 2 ranges of PrEP effectiveness. For the lowest effectiveness of PrEP (40%-60%), NOTE. PrEP, preexposure prophylaxis. a The efficiency of male-to-female HIV transmission is twice that of female-to-male transmission [39, 40] . Therefore, the transmission probability used here was set at twice the value of 0.0035-0.0091, which was previously reported by Baeten et al. [29] for male Kenyan truck drivers.
b The M184V mutation reduces the median viral load by 50% [11] . Note that log 10 (xy) ϭ log 10 (x) ϩ log 10 (y); thus, a 50% reduction can be written as log 10 (0.5y) ϭ log 10 (0.5) ϩ log 10 (y), or 0.30 should be subtracted from the log 10 wild-type viral load.
the median risk is anticipated to be reduced by 22% (interquartile range, 10%-33%). Increasing the effectiveness of PrEP to 60%-80% resulted, as expected, in a higher median risk reduction of 33% (interquartile range, 16%-49%).
The minimum risk reductions in table 2 are Ͻ0, indicating that the risk of acquiring HIV infection could potentially increase after the introduction of PrEP. We found that the simulations with an increased and a decreased risk reduction had different values for the parameters used to predict future use of PrEP (␣, , and ). 
The association between the risk reduction and the effectiveness of PrEP, ranging from 0 (no impact on transmission) through 1 (prevention of all new infections), is shown in figure 1 . Importantly, the figure shows that PrEP could already have a beneficial impact at relatively limited levels of effectiveness. For instance, the median risk reduction (as indicated by the black line between the orange and yellow area in figure 1 ) was 0 if PrEP Sensitivity analysis for absence of drug resistance. We determined which factors were most strongly associated with the monthly risk of HIV infection with use of a sensitivity analysis (table 3) . General variables, such as the number of sexual acts per month (PRCC, 0.9), prevalence of HIV infection (PRCC, 0.9), and transmissibility of HIV (PRCC, 0.7), were most strongly associated with the risk of infection. Importantly, the PRCC values for these variables were similar before and after introduction of PrEP. Conversely, the effectiveness by which condoms and PrEP were expected to reduce the transmissibility of HIV were associated with a lower risk of infection (PRCC, Ϫ0.04 for condoms and Ϫ0.15 for PrEP).
The sensitivity analysis of the risk reduction showed which factors were most strongly associated with a decrease in the incidence of new HIV infections after PrEP availability (table 3). The strongest predictor of an increased risk of infection was found to be the level of condom use before PrEP was introduced (PRCC of 0.42 for the lowest and 0.27 for the highest level of PrEP efficiency). This is explained by the assumed higher effectiveness of condoms in preventing infection, compared with PrEP. The use of PrEP as the only protection measure was another determinant that was strongly associated with an increased risk (PRCC of 0.31 for the lowest and 0.09 for the highest level of PrEP efficiency). The high coefficients for both initial condom use and PrEP use as the only protection measure indicate that condom replacement could lead to a higher incidence of HIV infection.
The magnitude of the effectiveness by which PrEP use reduces the transmissibility of HIV most strongly predicts the risk reduction (PRCC of Ϫ0.80 if no drug-resistant strains are circulating). Similarly, we found that the use of PrEP for sexual acts in which currently no condoms are used is an important factor associated with a higher risk reduction (Ϫ0.57 and Ϫ0.70 for the lowest and highest effectiveness of PrEP, respectively).
Impact of PrEP on monthly risk of acquiring HIV infection in the presence of drug resistance. Figure 2 shows the association between the risk reduction and the prevalence of drugresistant HIV infection. In the scenario in which drug-resistant strains are associated with a reduced transmissibility, drug resistance does not have an impact at the lowest effectiveness of PrEP. This observation is illustrated by a comparison of the risk reduc- NOTE. The partial rank correlation coefficients were, in general, similar for the analysis based on a PrEP effectiveness of 40%-60% and that based on a PrEP effectiveness of 60%-80%. Therefore, the table includes the partial rank correlation coefficient values for a PrEP effectiveness of 40%-60%. The partial rank correlation coefficients for the highest PrEP effectiveness are only listed when the value differed by Ͼ0.05. PrEP, preexposure prophylaxis. Value for the highest PrEP effectiveness is given in parenthesis.
tions achieved with the assumption that 10% versus 50% of the circulating strains are drug resistant. At a 10% prevalence of drug-resistant strains, the anticipated risk reduction was 21%; this is similar to the 19% decrease calculated on the basis of the assumption that 50% of circulating strains were drug resistant. This indicates that a detrimental impact of drug-resistant HIV infection on the effectiveness of PrEP can be counterbalanced by a reduced transmissibility.
The assumption of no change in the fitness resulted in a beneficial risk reduction of 20% (interquartile range, 9%-30%) if 10% of all circulating HIV strains were assumed to be resistant to PrEP agents. In the absence of a fitness cost, drug resistance will, however, have a greater impact, because the risk reduction would be reduced to 12% (interquartile range, 5%-20%) if 50% of all circulating HIV strains were resistant.
At the highest effectiveness of PrEP that we analyzed, we found that, in the presence of a fitness cost, the median monthly risk reduction ranged from 33% (interquartile range, 16%-49%) in the absence of drug resistance to 26% (interquartile range, 16%-37%) if 50% of all virus strains were assumed to be resistant. In the absence of a fitness cost, the median risk of infection was reduced by at least 19% (interquartile range, 8%-29%) at a 50% prevalence of drug-resistant strains.
Sensitivity analysis for drug resistance. Drug resistance reduces the PRCC values of factors that are associated with an increased risk after PrEP availability (table 3) . For instance, the coefficient for condom use before PrEP availability is reduced from 0.42 to 0.38 (PrEP effectiveness, 40%-60%). Therefore, drug resistance reduces the harm caused by variables that are associated with an increased risk. Drug resistance, however, also reduces the benefit of some variables, such as the effectiveness by which PrEP reduces transmissibility (PRCC increases from Ϫ0.80 to Ϫ0.63 in the presence of drug resistance) and receipt of antiretrovirals for sexual acts in which no protection is currently used (PRCC increases from Ϫ0.57 to Ϫ0.40).
As expected, the magnitude by which drug resistance reduces transmissibility is associated with a stronger risk reduction than that associated with other variables. The level by which drug resistance reduces the effectiveness of PrEP is inversely related to the risk reduction.
DISCUSSION
In this study, we used risk equations to evaluate the potential impact of PrEP administered before exposure to HIV. We found that the introduction of PrEP can reduce the number of new infections, but its success will depend on several factors. First, circulating drug resistance was predicted to have a limited impact on the effectiveness of PrEP. Second, the number of new infections could increase if condoms are frequently replaced by PrEP, under the assumption that the latter is less effective in reducing the transmissibility of the virus. Finally, the number of new infections will decrease if there is a high rate of PrEP use for sexual acts in which currently no condoms are used.
Mathematical models are inherently limited by the assumptions that are used to construct them [21] . The results of mathematical models, therefore, provide predictions given a range of possibilities. These predictions depend on the reliability of the In A and B, it was assumed that preexposure prophylaxis would reduce the transmissibility of HIV infection by 40%-60%. In C and D, it was assumed that this effectiveness was 60%-80%. In the analysis of A and C, a fitness cost was included by assuming that drug-resistant HIV strains are less fit and, therefore, less easily transmissible. This fitness cost was not included in the analysis for B and D.
data. We will, therefore, discuss the parameters and the ranges of those parameters that were used in our model.
Reliable information about the proportion of sexual acts in which a particular mode of protection is used is important, because it determines the magnitude of the risk of HIV infection. From the literature, we obtained estimates for condom use among young women in Zimbabwe. These estimates are similar to figures reported elsewhere in Africa [14, 22, 23] . However, only limited information is available concerning determinants for future PrEP use and condom replacement [24] . To address this uncertainty, wide ranges were taken for the proportion of sexual acts in which a particular type of protection will be used after PrEP becomes available.
Another important variable is the effectiveness of PrEP in reducing the risk of infection due to HIV. The precise effectiveness of PrEP in humans is unknown. Therefore, the values for the effectiveness of PrEP (40%-80%) were derived from studies involving macaques [2] [3] [4] [5] .
Other variables included in the model were prevalence of HIV infection [14, [25] [26] [27] [28] , transmissibility of HIV [29] , and the number of sexual acts [14] . Importantly, the sensitivity analysis showed that these factors have only a limited impact on the risk reduction. It should, however, be noted that our model assumed that the magnitude of these variables would not change after PrEP became available. It is likely that the transmissibility of HIV and the prevalence (in the short term) will remain unchanged. However, an increase in risk behavior (e.g., a higher number of sexual acts) may lead to more new infections.
The impact of circulating drug resistance was analyzed using a wide range for the prevalence of drug-resistant strains. The upper limit of the range was 50%, which is the prevalence of M184V (which causes resistance to emtricitabine) in a population of patients experiencing treatment failure. M184V is the most frequently occurring drug resistance-associated amino acid substitution in patients who experience treatment failure [10, 12] . The prevalence of 50% is an overestimation, because recent studies have reported that approximately one-half of all new infections are attributable to contact with an individual who has acute infection [30] . The prevalence of transmitted drug-resistant infection among patients with acute infection patients is lower and ranges from 0% through 25% [31] . Therefore, the impact of drug resistance may be less than that reported in this article.
The magnitude by which drug resistance will reduce the effectiveness of PrEP is unknown. Antiretroviral drugs frequently show some limited effectiveness against drug-resistant virus [32] . Therefore, we assumed that drug resistance reduces the effectiveness of PrEP by 50%-90%. Studies of monotherapy with lamivudine that were performed before HAART became available showed that M184V reduced the median viral load by ϳ50% [11] , which, on a logarithmic scale, is the same as a reduction of ϳ30%.
Other studies have also predicted that PrEP could be beneficial for the prevention of new infections due to HIV [33] [34] [35] . Two of these studies did not consider the impact of drug resistance on PrEP [34, 35] . However, it is likely that drug resistance will emerge and be transmitted, as has been shown in countries with access to treatment [31, 36] . Abbas et al. [33] considered drug resistance but did not include use of condoms. Therefore, the added value of our study is that we incorporated the potential impact of drug resistance and condom use.
Drug resistance caused by the use of PrEP could limit future options. We did not predict whether drug resistance will emerge because of the use of PrEP. We did, however, use a period of 1 month after the introduction of PrEP. It is expected that the prevalence of drug-resistant HIV infection will remain fairly unchanged during this period. Nonetheless, our model indicates that such resistance will only have a very modest influence on the effectiveness of PrEP.
The parameters and their ranges were obtained from Zimbabwe. The ranges of relevant parameters, such as the prevalence of HIV infection and the prevalence of condom use, could be different in other parts of the world. For instance, several studies have reported higher rates of condom use among men who have sex with men in some parts of the United States [37, 38] . As a consequence, the results might not apply to other populations.
On the basis of the assumptions and parameter ranges used in this study, we conclude that PrEP could be associated with a reduction in the risk of acquiring HIV infection. PrEP must only be implemented after randomized, controlled studies have shown that it is safe and effective. We found that the precise impact of PrEP will depend on many factors, such as the prevalence of condom use, the frequency with which condom use is replaced by PrEP after the latter becomes available, the number of sexual acts performed, the effectiveness of PrEP, and the level of PrEP use among individuals who are currently not using condoms. Because changes in risk behavior could lead to more new infections, PrEP must be introduced in combination with behavioral education. Circulating drug resistance will have only a limited impact on the effectiveness of PrEP.
